Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also ...

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia Therapeutics, Inc. ('Intellia Therapeutics, Inc.') ...

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for future growth. Click for more on NTLA.

said it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and discontinue development of NTLA-3001, which will result in the company cutting around 27% of its workforce.

Intellia Therapeutics shifts focus to NTLA-2002 for hereditary angioedema and nex-z for ATTR amyloidosis, advancing Phase 3 trials in 2025. Strategic reorganization includes a 27% workforce ...